High Fructose Diet, the Gut Microbiome, and Metabolic Health
NCT ID: NCT06329544
Last Updated: 2025-12-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2024-10-08
2028-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The research team aims to:
1. Determine the relationships between high fructose consumption, the gut microbiome and metabolic risk.
2. Characterize the causal role(s) that fructose-induced alterations to the gut microbiome have on metabolic risk using a germ-free mouse model.
The research team will measure 1) microbiota community structure and function via metagenomic sequencing of stool, 2) fecal metabolites via targeted and untargeted metabolomics, 3) anthropometrics, 4) insulin resistance, serum markers of T2D risk and inflammatory cytokines, 5) fecal microbial carbohydrate oxidation capacity and 6) liver fat via MRI elastography. The research team will use novel statistical approaches, including Distributed Lag Modeling, to understand the complex relationships between diet, the microbiome, metabolites and health outcomes.
The research team will then conduct controlled dietary interventions and fecal microbiome transplantation studies in germ-free mice. Donor fecal samples from human participants in both the glucose and fructose arms of the clinical intervention will be transplanted into germ-free and colonized mice to establish a causal relationship between fructose-induced changes to the gut microbiome, liver fat and metabolic and inflammatory changes known to increase risk for T2D.
The research team aims to comprehensively assess the structural and functional changes to the gut microbiome brought about by a high fructose diet. Determining the impact of excess fructose on the microbiome will help identify novel means by which fructose contributes to metabolic disease risk. In addition to identifying strategies to improve metabolic health in adults, data from this proposal could help inform targeted approaches to mitigate future disease risk in vulnerable populations that consume high levels of fructose, such as children.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Glucose Dietary then Fructose Dietary
Participants that will be randomized to the 12-day isocaloric weight-maintaining high glucose diet, then will change to the12-day isocaloric weight-maintaining high fructose diet after a 10-day washout period.
Fructose
12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)
glucose
12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)
Fructose Dietary then Glucose Dietary
Participants that will be randomized to the 12-day isocaloric weight-maintaining high fructose diet, then will change to the 12-day isocaloric weight-maintaining high glucose diet after a 10-day washout period.
Fructose
12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)
glucose
12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fructose
12-day isocaloric weight-maintaining high fructose diet (25% total calories from added fructose)
glucose
12-day isocaloric weight-maintaining high glucose diet (25% total calories from added glucose)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Consumption of \> 1 sugar sweetened beverage per day
* Antibiotics within 3 months prior to enrollment or during intervention
* Vegetarian, vegan or other restrictive dietary habits
* Food allergy
* Alcohol consumption in excess of 2 drink per day
* Physician diagnosis of a major medical illness (including type 1 or type 2 diabetes) or eating disorder
* Physical, mental, or cognitive handicaps that prevent participation
* Chronic use of any medication that may affect body weight or composition, insulin resistance, or lipid profiles;
* Current smoking (more than 1 cigarette in the past week) or use of other recreational drugs; e) restrictive dietary habits;
* food allergy;
* excess alcohol consumption;
* recent use of pro-, pre- or Synbiotics of receipt of antibiotics within 3 months prior to enrollment or during the intervention;
* consumption of greater than 1 sugar sweetened beverage per day prior to enrollment
25 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Metabolic Solutions Inc.
INDUSTRY
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Icahn School of Medicine at Mount Sinai
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ryan Walker
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ryan Walker
Role: PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mount Sinai Morningside
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY-23-01572
Identifier Type: -
Identifier Source: org_study_id